Logo

Gene Editing Shop Recombinetics Surpasses $2M Fundraising Goal

Jul 30, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Gene editing firm Recombinetics today said that it surpassed its $2 million fundraising goal this month.

The St. Paul, Minn.-based firm did not disclose its investors.

Founded in 2008, Recombinetics is using a gene editing technology called TALENs to produce its first biomedical product and to develop the first agricultural products, it said on its website.

TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Recombinetics has secured $3.4 million in private investments since its founding. It also has brought in $1.5 million in development program funding through contracts with the animal agriculture industry, grants from the US Department of Agriculture, and contracts with the National Institutes of Health, the company said.

Filed under

Genetic Research
gene editing
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.